Showing 20 of 27 recruiting trials for “obsolete-hiv-related-hodgkin-lymphoma”
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
RecruitingNCT07313943 ↗
PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE
Amping up With PemJAK
RecruitingNCT07356882 ↗
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
👨⚕️ Mathieu SIMONIN, MD, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Nov 2025View details ↗
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
👨⚕️ Christina Dieli-Conwright, MD, PhD, Dana-Farber Cancer Institute📍 1 site📅 Started Jun 2025View details ↗
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
👨⚕️ Randall Michael, MD, University of California, San Francisco📍 1 site📅 Started Oct 2024View details ↗
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
👨⚕️ Andreas Engert, Prof., 1st Department of Medicine, Cologne Universit Hospital📍 1 site📅 Started Mar 2024View details ↗
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
👨⚕️ Jelle Kijlstra, MD, MBA, BobcatBio, p/k/a SIRPant Immunotherapeutics📍 3 sites📅 Started Jan 2024View details ↗
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
👨⚕️ Indapta Therapeutics, Inc., Indapta Therapeutics, INC.📍 12 sites📅 Started Oct 2023View details ↗
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
Improving Exercise Capacity With a Tailored Physical Activity Intervention
👨⚕️ William Hundley, MD, Wake Forest Baptist Comprehensive Cancer Center📍 2 sites📅 Started Mar 2023View details ↗
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →